Organoids refer to tissue analogs with a certain spatial structure formed by culturing adult stem cells or pluripotent stem cells in a in vitro three-dimensional environment. Organoids are highly consistent with the source tissue in terms of tissue structure, cell types, self-renewal capacity, and function, thereby demonstrating unique advantages in various biomedical fields such as developmental biology, disease modeling, precision medicine, drug discovery, gene and cell therapy, infection and immunology, and regenerative medicine.

bioGenous is dedicated to providing standardized and modular organoid products and technical support for biomedical scientific research, drug discovery, and clinical precision medicine. Currently, it has served over 200 new drug R&D enterprises, tertiary hospitals, and scientific research institutions, offering organoid automation equipment, whole-process reagent kits for multiple tissues, technical solutions for organoid culture and sample library construction, organoid drug discovery and precision medicine subsystems, etc. With internationally leading organoid technology and independent intellectual property rights, bioGenous aims to become an upstream unicorn in the industry and lead a modeling revolution across multiple biomedical fields.